Osiris Therapeutics, Inc. , announced today that its multi-center, randomized, controlled clinical trial evaluating the safety and effectiveness of GrafixA for the treatment of chronic diabetic foot ulcers has been accepted for podium presentation at the upcoming Symposium on Advanced Wound Care in Las Vegas on Friday, September 27, 2013.
http://www.businesswire.com/news/topix/20130905006632/en
http://www.businesswire.com/news/topix/20130905006632/en
No comments:
Post a Comment